5JK Stock Overview
ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ISR Immune System Regulation Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.11 |
| 52 Week High | SEK 0.78 |
| 52 Week Low | SEK 0.11 |
| Beta | 0.54 |
| 11 Month Change | 0% |
| 3 Month Change | -44.53% |
| 1 Year Change | -77.11% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 2.5% |
| 1Y | -77.1% | -16.5% | 8.6% |
Return vs Industry: 5JK underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 5JK underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 5JK volatility | |
|---|---|
| 5JK Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5JK's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 5JK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 6 | Ola Winqvist | israb.se |
ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden. Its product pipeline includes Covid-19 vaccine, hepatitis B (HBV), human immunodeficiency virus (HIV), and oncology drugs. The company was founded in 2007 and is headquartered in Solna, Sweden.
ISR Immune System Regulation Holding AB (publ) Fundamentals Summary
| 5JK fundamental statistics | |
|---|---|
| Market cap | €8.69m |
| Earnings (TTM) | -€23.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 5JK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JK income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 257.16m |
| Earnings | -SEK 257.16m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -0.6% |
How did 5JK perform over the long term?
See historical performance and comparison